- call +1-201-465-4211
- email sales@mrinsights.biz
Cancer Janus Kinase Inhibitors
Scope of the Report:
The conventional modes of cancer management including surgery, radiotherapy and chemotherapy were discarded as an aspirant for the future of cancer management long back ago. The arrival of modern cancer treatment modalities like immunotherapy and targeted therapy revolutionized the outlook of the future of cancer management. Amongst both of the modern therapies, targeted therapies have shown an impressive growth in a very short duration of time. The targeted therapies developed rapidly and gained much importance in the global market for cancer therapeutics due to their advantages over the conventional therapies. Targeted therapies are safer and more efficient approach for managing cancer. The only drawback for targeted therapies was that only a few targets were available for developing cancer therapeutics. The high efficacy of targeted therapeutics for cancer raised the demand for identifying new targets.
The worldwide market for Cancer Janus Kinase Inhibitors is expected to grow at a CAGR of roughly xx% over the next five years, will reach xx million US$ in 2023, from xx million US$ in 2017, according to a new GIR (Global Info Research) study.
This report focuses on the Cancer Janus Kinase Inhibitors in global market, especially in North America, Europe and Asia-Pacific, South America, Middle East and Africa. This report categorizes the market based on manufacturers, regions, type and application.
Market Segment by Manufacturers, this report covers
Abbott Laboratories
Asana Biosciences
Astra Zeneca
Celon Pharmaceuticals
Dynamic Pharma
Eli Lilly
Gilead Sciences
Hanmi Pharmaceuticals
Incyte
Kyowa Hakko
Moleculin
Pfizer
PIQUR Therapeutics
Portola Pharmaceuticals
S-BIO
Market Segment by Regions, regional analysis covers
North America (United States, Canada and Mexico)
Europe (Germany, France, UK, Russia and Italy)
Asia-Pacific (China, Japan, Korea, India and Southeast Asia)
South America (Brazil, Argentina, Colombia etc.)
Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)
Market Segment by Type, covers
Ruxolitinib
Momelotinib
Lestaurtinib
Pacritinib
Market Segment by Applications, can be divided into
Hospitals
Ambulatory Surgical Centers
Others
There are 15 Chapters to deeply display the global Cancer Janus Kinase Inhibitors market.
Chapter 1, to describe Cancer Janus Kinase Inhibitors Introduction, product scope, market overview, market opportunities, market risk, market driving force;
Chapter 2, to analyze the top manufacturers of Cancer Janus Kinase Inhibitors, with sales, revenue, and price of Cancer Janus Kinase Inhibitors, in 2016 and 2017;
Chapter 3, to display the competitive situation among the top manufacturers, with sales, revenue and market share in 2016 and 2017;
Chapter 4, to show the global market by regions, with sales, revenue and market share of Cancer Janus Kinase Inhibitors, for each region, from 2013 to 2018;
Chapter 5, 6, 7, 8 and 9, to analyze the market by countries, by type, by application and by manufacturers, with sales, revenue and market share by key countries in these regions;
Chapter 10 and 11, to show the market by type and application, with sales market share and growth rate by type, application, from 2013 to 2018;
Chapter 12, Cancer Janus Kinase Inhibitors market forecast, by regions, type and application, with sales and revenue, from 2018 to 2023;
Chapter 13, 14 and 15, to describe Cancer Janus Kinase Inhibitors sales channel, distributors, traders, dealers, Research Findings and Conclusion, appendix and data source
The base year for the study has been considered 2019, historic year 2014 and 2018, the forecast period considered is from 2020 to 2027. The regions analyzed for the market include North America, Europe, South America, Asia Pacific, and Middle East and Africa. These regions are further analyzed at the country-level. The study also includes attractiveness analysis of type, application and regions which are benchmarked based on their market size, growth rate and attractiveness in terms of present and future opportunity for understanding the future growth of the market.
Market is segmented on the basis:
The report offers in-depth analysis of driving factors, opportunities, restraints, and challenges for gaining the key insight of the market. The report emphasizes on all the key trends that play a vital role in the enlargement of the market from 2019 to 2026.
The report provides company profile of the key players operating in the market and a comparative analysis based on their business overviews industry offering, segment market share, regional presence, business strategies, innovations, mergers & acquisitions, recent developments, joint venture, collaborations, partnerships, SWOT analysis, and key financial information.
Table of Contents
1 Market Overview
1.1 Cancer Janus Kinase Inhibitors Introduction
1.2 Market Analysis by Type
1.2.1 Ruxolitinib
1.2.2 Momelotinib
1.2.3 Lestaurtinib
1.2.4 Pacritinib
1.3 Market Analysis by Applications
1.3.1 Hospitals
1.3.2 Ambulatory Surgical Centers
1.3.3 Others
1.4 Market Analysis by Regions
1.4.1 North America (United States, Canada and Mexico)
1.4.1.1 United States Market States and Outlook (2013-2023)
1.4.1.2 Canada Market States and Outlook (2013-2023)
1.4.1.3 Mexico Market States and Outlook (2013-2023)
1.4.2 Europe (Germany, France, UK, Russia and Italy)
1.4.2.1 Germany Market States and Outlook (2013-2023)
1.4.2.2 France Market States and Outlook (2013-2023)
1.4.2.3 UK Market States and Outlook (2013-2023)
1.4.2.4 Russia Market States and Outlook (2013-2023)
1.4.2.5 Italy Market States and Outlook (2013-2023)
1.4.3 Asia-Pacific (China, Japan, Korea, India and Southeast Asia)
1.4.3.1 China Market States and Outlook (2013-2023)
1.4.3.2 Japan Market States and Outlook (2013-2023)
1.4.3.3 Korea Market States and Outlook (2013-2023)
1.4.3.4 India Market States and Outlook (2013-2023)
1.4.3.5 Southeast Asia Market States and Outlook (2013-2023)
1.4.4 South America, Middle East and Africa
1.4.4.1 Brazil Market States and Outlook (2013-2023)
1.4.4.2 Egypt Market States and Outlook (2013-2023)
1.4.4.3 Saudi Arabia Market States and Outlook (2013-2023)
1.4.4.4 South Africa Market States and Outlook (2013-2023)
1.4.4.5 Nigeria Market States and Outlook (2013-2023)
1.5 Market Dynamics
1.5.1 Market Opportunities
1.5.2 Market Risk
1.5.3 Market Driving Force
2 Manufacturers Profiles
2.1 Abbott Laboratories
2.1.1 Business Overview
2.1.2 Cancer Janus Kinase Inhibitors Type and Applications
2.1.2.1 Product A
2.1.2.2 Product B
2.1.3 Abbott Laboratories Cancer Janus Kinase Inhibitors Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.2 Asana Biosciences
2.2.1 Business Overview
2.2.2 Cancer Janus Kinase Inhibitors Type and Applications
2.2.2.1 Product A
2.2.2.2 Product B
2.2.3 Asana Biosciences Cancer Janus Kinase Inhibitors Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.3 Astra Zeneca
2.3.1 Business Overview
2.3.2 Cancer Janus Kinase Inhibitors Type and Applications
2.3.2.1 Product A
2.3.2.2 Product B
2.3.3 Astra Zeneca Cancer Janus Kinase Inhibitors Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.4 Celon Pharmaceuticals
2.4.1 Business Overview
2.4.2 Cancer Janus Kinase Inhibitors Type and Applications
2.4.2.1 Product A
2.4.2.2 Product B
2.4.3 Celon Pharmaceuticals Cancer Janus Kinase Inhibitors Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.5 Dynamic Pharma
2.5.1 Business Overview
2.5.2 Cancer Janus Kinase Inhibitors Type and Applications
2.5.2.1 Product A
2.5.2.2 Product B
2.5.3 Dynamic Pharma Cancer Janus Kinase Inhibitors Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.6 Eli Lilly
2.6.1 Business Overview
2.6.2 Cancer Janus Kinase Inhibitors Type and Applications
2.6.2.1 Product A
2.6.2.2 Product B
2.6.3 Eli Lilly Cancer Janus Kinase Inhibitors Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.7 Gilead Sciences
2.7.1 Business Overview
2.7.2 Cancer Janus Kinase Inhibitors Type and Applications
2.7.2.1 Product A
2.7.2.2 Product B
2.7.3 Gilead Sciences Cancer Janus Kinase Inhibitors Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.8 Hanmi Pharmaceuticals
2.8.1 Business Overview
2.8.2 Cancer Janus Kinase Inhibitors Type and Applications
2.8.2.1 Product A
2.8.2.2 Product B
2.8.3 Hanmi Pharmaceuticals Cancer Janus Kinase Inhibitors Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.9 Incyte
2.9.1 Business Overview
2.9.2 Cancer Janus Kinase Inhibitors Type and Applications
2.9.2.1 Product A
2.9.2.2 Product B
2.9.3 Incyte Cancer Janus Kinase Inhibitors Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.10 Kyowa Hakko
2.10.1 Business Overview
2.10.2 Cancer Janus Kinase Inhibitors Type and Applications
2.10.2.1 Product A
2.10.2.2 Product B
2.10.3 Kyowa Hakko Cancer Janus Kinase Inhibitors Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.11 Moleculin
2.11.1 Business Overview
2.11.2 Cancer Janus Kinase Inhibitors Type and Applications
2.11.2.1 Product A
2.11.2.2 Product B
2.11.3 Moleculin Cancer Janus Kinase Inhibitors Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.12 Pfizer
2.12.1 Business Overview
2.12.2 Cancer Janus Kinase Inhibitors Type and Applications
2.12.2.1 Product A
2.12.2.2 Product B
2.12.3 Pfizer Cancer Janus Kinase Inhibitors Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.13 PIQUR Therapeutics
2.13.1 Business Overview
2.13.2 Cancer Janus Kinase Inhibitors Type and Applications
2.13.2.1 Product A
2.13.2.2 Product B
2.13.3 PIQUR Therapeutics Cancer Janus Kinase Inhibitors Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.14 Portola Pharmaceuticals
2.14.1 Business Overview
2.14.2 Cancer Janus Kinase Inhibitors Type and Applications
2.14.2.1 Product A
2.14.2.2 Product B
2.14.3 Portola Pharmaceuticals Cancer Janus Kinase Inhibitors Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.15 S-BIO
2.15.1 Business Overview
2.15.2 Cancer Janus Kinase Inhibitors Type and Applications
2.15.2.1 Product A
2.15.2.2 Product B
2.15.3 S-BIO Cancer Janus Kinase Inhibitors Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
3 Global Cancer Janus Kinase Inhibitors Sales, Revenue, Market Share and Competition by Manufacturer (2016-2017)
3.1 Global Cancer Janus Kinase Inhibitors Sales and Market Share by Manufacturer (2016-2017)
3.2 Global Cancer Janus Kinase Inhibitors Revenue and Market Share by Manufacturer (2016-2017)
3.3 Market Concentration Rate
3.3.1 Top 3 Cancer Janus Kinase Inhibitors Manufacturer Market Share in 2017
3.3.2 Top 6 Cancer Janus Kinase Inhibitors Manufacturer Market Share in 2017
3.4 Market Competition Trend
4 Global Cancer Janus Kinase Inhibitors Market Analysis by Regions
4.1 Global Cancer Janus Kinase Inhibitors Sales, Revenue and Market Share by Regions
4.1.1 Global Cancer Janus Kinase Inhibitors Sales and Market Share by Regions (2013-2018)
4.1.2 Global Cancer Janus Kinase Inhibitors Revenue and Market Share by Regions (2013-2018)
4.2 North America Cancer Janus Kinase Inhibitors Sales and Growth Rate (2013-2018)
4.3 Europe Cancer Janus Kinase Inhibitors Sales and Growth Rate (2013-2018)
4.4 Asia-Pacific Cancer Janus Kinase Inhibitors Sales and Growth Rate (2013-2018)
4.5 South America Cancer Janus Kinase Inhibitors Sales and Growth Rate (2013-2018)
4.6 Middle East and Africa Cancer Janus Kinase Inhibitors Sales and Growth Rate (2013-2018)
5 North America Cancer Janus Kinase Inhibitors by Countries
5.1 North America Cancer Janus Kinase Inhibitors Sales, Revenue and Market Share by Countries
5.1.1 North America Cancer Janus Kinase Inhibitors Sales and Market Share by Countries (2013-2018)
5.1.2 North America Cancer Janus Kinase Inhibitors Revenue and Market Share by Countries (2013-2018)
5.2 United States Cancer Janus Kinase Inhibitors Sales and Growth Rate (2013-2018)
5.3 Canada Cancer Janus Kinase Inhibitors Sales and Growth Rate (2013-2018)
5.4 Mexico Cancer Janus Kinase Inhibitors Sales and Growth Rate (2013-2018)
6 Europe Cancer Janus Kinase Inhibitors by Countries
6.1 Europe Cancer Janus Kinase Inhibitors Sales, Revenue and Market Share by Countries
6.1.1 Europe Cancer Janus Kinase Inhibitors Sales and Market Share by Countries (2013-2018)
6.1.2 Europe Cancer Janus Kinase Inhibitors Revenue and Market Share by Countries (2013-2018)
6.2 Germany Cancer Janus Kinase Inhibitors Sales and Growth Rate (2013-2018)
6.3 UK Cancer Janus Kinase Inhibitors Sales and Growth Rate (2013-2018)
6.4 France Cancer Janus Kinase Inhibitors Sales and Growth Rate (2013-2018)
6.5 Russia Cancer Janus Kinase Inhibitors Sales and Growth Rate (2013-2018)
6.6 Italy Cancer Janus Kinase Inhibitors Sales and Growth Rate (2013-2018)
7 Asia-Pacific Cancer Janus Kinase Inhibitors by Countries
7.1 Asia-Pacific Cancer Janus Kinase Inhibitors Sales, Revenue and Market Share by Countries
7.1.1 Asia-Pacific Cancer Janus Kinase Inhibitors Sales and Market Share by Countries (2013-2018)
7.1.2 Asia-Pacific Cancer Janus Kinase Inhibitors Revenue and Market Share by Countries (2013-2018)
7.2 China Cancer Janus Kinase Inhibitors Sales and Growth Rate (2013-2018)
7.3 Japan Cancer Janus Kinase Inhibitors Sales and Growth Rate (2013-2018)
7.4 Korea Cancer Janus Kinase Inhibitors Sales and Growth Rate (2013-2018)
7.5 India Cancer Janus Kinase Inhibitors Sales and Growth Rate (2013-2018)
7.6 Southeast Asia Cancer Janus Kinase Inhibitors Sales and Growth Rate (2013-2018)
8 South America Cancer Janus Kinase Inhibitors by Countries
8.1 South America Cancer Janus Kinase Inhibitors Sales, Revenue and Market Share by Countries
8.1.1 South America Cancer Janus Kinase Inhibitors Sales and Market Share by Countries (2013-2018)
8.1.2 South America Cancer Janus Kinase Inhibitors Revenue and Market Share by Countries (2013-2018)
8.2 Brazil Cancer Janus Kinase Inhibitors Sales and Growth Rate (2013-2018)
8.3 Argentina Cancer Janus Kinase Inhibitors Sales and Growth Rate (2013-2018)
8.4 Colombia Cancer Janus Kinase Inhibitors Sales and Growth Rate (2013-2018)
9 Middle East and Africa Cancer Janus Kinase Inhibitors by Countries
9.1 Middle East and Africa Cancer Janus Kinase Inhibitors Sales, Revenue and Market Share by Countries
9.1.1 Middle East and Africa Cancer Janus Kinase Inhibitors Sales and Market Share by Countries (2013-2018)
9.1.2 Middle East and Africa Cancer Janus Kinase Inhibitors Revenue and Market Share by Countries (2013-2018)
9.2 Saudi Arabia Cancer Janus Kinase Inhibitors Sales and Growth Rate (2013-2018)
9.3 UAE Cancer Janus Kinase Inhibitors Sales and Growth Rate (2013-2018)
9.4 Egypt Cancer Janus Kinase Inhibitors Sales and Growth Rate (2013-2018)
9.5 Nigeria Cancer Janus Kinase Inhibitors Sales and Growth Rate (2013-2018)
9.6 South Africa Cancer Janus Kinase Inhibitors Sales and Growth Rate (2013-2018)
10 Global Cancer Janus Kinase Inhibitors Market Segment by Type
10.1 Global Cancer Janus Kinase Inhibitors Sales, Revenue and Market Share by Type (2013-2018)
10.1.1 Global Cancer Janus Kinase Inhibitors Sales and Market Share by Type (2013-2018)
10.1.2 Global Cancer Janus Kinase Inhibitors Revenue and Market Share by Type (2013-2018)
10.2 Ruxolitinib Sales Growth and Price
10.2.1 Global Ruxolitinib Sales Growth (2013-2018)
10.2.2 Global Ruxolitinib Price (2013-2018)
10.3 Momelotinib Sales Growth and Price
10.3.1 Global Momelotinib Sales Growth (2013-2018)
10.3.2 Global Momelotinib Price (2013-2018)
10.4 Lestaurtinib Sales Growth and Price
10.4.1 Global Lestaurtinib Sales Growth (2013-2018)
10.4.2 Global Lestaurtinib Price (2013-2018)
10.5 Pacritinib Sales Growth and Price
10.5.1 Global Pacritinib Sales Growth (2013-2018)
10.5.2 Global Pacritinib Price (2013-2018)
11 Global Cancer Janus Kinase Inhibitors Market Segment by Application
11.1 Global Cancer Janus Kinase Inhibitors Sales Market Share by Application (2013-2018)
11.2 Hospitals Sales Growth (2013-2018)
11.3 Ambulatory Surgical Centers Sales Growth (2013-2018)
11.4 Others Sales Growth (2013-2018)
12 Cancer Janus Kinase Inhibitors Market Forecast (2018-2023)
12.1 Global Cancer Janus Kinase Inhibitors Sales, Revenue and Growth Rate (2018-2023)
12.2 Cancer Janus Kinase Inhibitors Market Forecast by Regions (2018-2023)
12.2.1 North America Cancer Janus Kinase Inhibitors Market Forecast (2018-2023)
12.2.2 Europe Cancer Janus Kinase Inhibitors Market Forecast (2018-2023)
12.2.3 Asia-Pacific Cancer Janus Kinase Inhibitors Market Forecast (2018-2023)
12.2.4 South America Cancer Janus Kinase Inhibitors Market Forecast (2018-2023)
12.2.5 Middle East and Africa Cancer Janus Kinase Inhibitors Market Forecast (2018-2023)
12.3 Cancer Janus Kinase Inhibitors Market Forecast by Type (2018-2023)
12.3.1 Global Cancer Janus Kinase Inhibitors Sales Forecast by Type (2018-2023)
12.3.2 Global Cancer Janus Kinase Inhibitors Market Share Forecast by Type (2018-2023)
12.4 Cancer Janus Kinase Inhibitors Market Forecast by Application (2018-2023)
12.4.1 Global Cancer Janus Kinase Inhibitors Sales Forecast by Application (2018-2023)
12.4.2 Global Cancer Janus Kinase Inhibitors Market Share Forecast by Application (2018-2023)
13 Sales Channel, Distributors, Traders and Dealers
13.1 Sales Channel
13.1.1 Direct Marketing
13.1.2 Indirect Marketing
13.1.3 Marketing Channel Future Trend
13.2 Distributors, Traders and Dealers
14 Research Findings and Conclusion
15 Appendix
15.1 Methodology
15.2 Data Source
List of Tables and Figures
Figure Cancer Janus Kinase Inhibitors Picture
Table Product Specifications of Cancer Janus Kinase Inhibitors
Figure Global Sales Market Share of Cancer Janus Kinase Inhibit
ProactiveWe manage our resources 24/7 to identify issues and address them before they become problems
Quality & ReliabilityWe are committed to providing reliable and highly accurate data with an excellent quality control system
Global Outreach6 Major regions and 40+ countries level analysis accomplished
Competitive PricingOur pricing strategy is highly competitive in the market, without compensating on the quality and the timeline of project delivery
